AOD-9604 vs HGH Fragment 176-191: Fat Loss Peptide Comparison

AOD-9604 and HGH Fragment 176-191 are closely related fat-loss peptides derived from the same region of human growth hormone. This guide explains their differences and helps researchers choose between them.

Quick Comparison Table

What Are These Peptides?

HGH Fragment 176-191

HGH Fragment 176-191 is the unmodified C-terminal fragment of human growth hormone:

• Sequence: Amino acids 176-191 of hGH
• Amino acids: 16
• Structure: Native/unmodified
• Discovery: Isolated as the lipolytic region of GH
• Status: Research compound

AOD-9604

AOD-9604 (Anti-Obesity Drug 9604) is a modified version of the same fragment:

• Sequence: HGH 176-191 + C-terminal tyrosine
• Amino acids: 17 (16 + Tyr)
• Structure: Modified for stability
• Discovery: Developed by Metabolic Pharmaceuticals
• Status: GRAS status (US), TGA approved (Australia, topical)

Mechanism: Same Core Action

Both peptides work through identical lipolytic mechanisms:

Shared Mechanism

1. Beta-3 adrenergic receptor activation on adipocytes
2. Hormone-sensitive lipase stimulation
3. Triglyceride hydrolysis → free fatty acids
4. Anti-lipogenic effects (prevent new fat formation)

What They Do NOT Do

This metabolic neutrality is their key advantage over full GH.

Structural Difference: The Tyrosine

HGH Fragment 176-191 Structure

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

AOD-9604 Structure

[Same sequence]-Tyr (C-terminal addition)

Why Add Tyrosine?

The C-terminal tyrosine modification:

Research Data Comparison

HGH Fragment 176-191 Evidence

Strengths:

• Original research compound
• Extensive preclinical data (Wu et al., 1993)
• Well-characterized mechanism
• Foundational studies established the fragment approach

Key Studies:

• Demonstration that aa 177-191 responsible for lipolysis
• Adipocyte studies showing fat breakdown
• No IGF-1 or glucose effects confirmed

AOD-9604 Evidence

Strengths:

• Clinical trials conducted (Phase I, II)
• Human safety data available
• Regulatory submissions (though not approved as drug)
• GRAS status in United States

Key Studies:

• Phase IIb trial in obese subjects
• Cartilage repair studies (osteoarthritis)
• Oral and injectable formulations tested

Which Has More Research?

Stability and Handling

HGH Fragment 176-191

AOD-9604

Practical Difference

The tyrosine modification in AOD-9604 provides:

• Slightly longer reconstituted stability
• More consistent batch-to-batch activity
• Better resistance to degradation during handling

Dosing Protocols

HGH Fragment 176-191 Dosing

AOD-9604 Dosing

Why Fasted Administration?

• Insulin inhibits lipolysis
• Fasted state maximizes fat mobilization
• Post-meal dosing reduces efficacy
• Pre-exercise timing may enhance effects

Cost Analysis

Cost-Effectiveness

Given similar mechanisms and modest potency differences:

• Budget priority: HGH Fragment 176-191
• Stability priority: AOD-9604

Efficacy Comparison

Do They Actually Work Differently?

Clinical Trial Reality

AOD-9604 Phase II results were mixed:

• Some studies showed fat reduction
• Others failed to meet primary endpoints
• Led to termination of obesity drug development
• Now pursued for osteoarthritis (different indication)

Important: Neither peptide achieved drug approval for obesity.

Research Applications

When to Use HGH Fragment 176-191

• Mechanism studies: Original compound, most literature
• Budget-conscious research: Lower cost
• Comparative studies: Standard reference
• Basic lipolysis research: Well-characterized

When to Use AOD-9604

• Stability-sensitive protocols: Enhanced stability
• Clinical translation research: Human trial data exists
• Long-duration studies: More stable reconstituted
• Regulatory-relevant work: Has regulatory history

Safety Profiles

Both compounds share excellent safety profiles:

Shared Safety Characteristics

Reported Effects

• Injection site reactions (occasional, mild)
• Transient redness (rare)
• No systemic side effects reported

Summary: Decision Framework

Conclusion

AOD-9604 and HGH Fragment 176-191 are fundamentally the same peptide with a minor structural modification. The C-terminal tyrosine in AOD-9604 provides modest improvements in stability and potentially potency, but the core mechanism and effects are identical.

For most research purposes, the choice comes down to practical considerations: HGH Fragment 176-191 offers lower cost and more published literature, while AOD-9604 offers better stability and existing human clinical data.

Neither should be expected to produce dramatic fat loss as standalone interventions—their utility lies in studying GH-mediated lipolysis pathways without the broader metabolic effects of full growth hormone.